• Publications
  • Influence
The Yale-Brown Obsessive Compulsive Scale. II. Validity.
Results from a previously reported placebo-controlled trial of fluvoxamine in 42 patients with obsessive-compulsive disorder showed that the Yale- Brown Scale was sensitive to drug-induced changes and that reductions in Yale-Brown Scale scores specifically reflected improvement in obsessive- compulsive disorder symptoms.
The Arizona Sexual Experience Scale (ASEX): reliability and validity.
The authors have developed the Arizona Sexual Experiences Scale (ASEX), a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm.
Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.
The behavioral effects of rapid tryptophan depletion in patients in antidepressant-induced remission and the therapeutic effects of some antidepressant drugs may be dependent on serotonin availability are investigated.
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
Depression: the case for a monoamine deficiency.
  • P. Delgado
  • Medicine
    The Journal of clinical psychiatry
  • 31 March 2000
It is clear that antidepressant agents in current use do indeed require intact monoamine systems for their therapeutic effect, however, some debate remains as to the precise role that a deficiency in monoamine system(s) may play in depression itself.
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.
A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder, lending partial support to the serotonin hypothesis of OCD.
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action
Depressive relapse during TRP depletion appears to be more related to antidepressant type than to patient variables since patients were randomly assigned to the two treatments, suggesting that antidepressants mediate their therapeutic effects through different mechanisms.
Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients.
That tryptophan depletion did not rapidly worsen depression argues that serotonin function is not linearly related to the level of depression and if reduced serotonin function does cause depression, then it is either as predisposing factor or due to a postsynaptic deficit in the utilization of serotonin.
Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine.
A higher baseline quality of life, living with spouse or partner, and having more education were the strongest predictors of response to acute pharmacotherapy among chronically depressed patients.
Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression.
The effects of rapid TRP depletion on mood in depressed patients is summarized and brain 5-HT function may be intimately involved in the modulation of some affective states and in the mechanism of action of some antidepressant medications.